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Abstract
Background: The Dbl-family of guanine nucleotide exchange factors (GEFs) activate the cytosolic
GTPases of the Rho family by enhancing the rate of exchange of GTP for GDP on the cognate
GTPase. This catalytic activity resides in the DH (Dbl-homology) domain, but typically GEFs are
multidomain proteins containing other modules. It is believed that GEFs are autoinhibited in the
cytosol due to supramodular architecture, and become activated in diverse signaling pathways
through conformational change and exposure of the DH domain, as the protein is translocated to
the membrane. A small family of RhoA-specific GEFs, containing the RGSL (regulators of G-protein
signaling-like) domain, act as effectors of select GPCRs via  Gα12/13, although the molecular
mechanism by which this pathway operates is not known. These GEFs include p115, LARG and
PDZRhoGEF (PRG).
Results: Here we show that the autoinhibition of PRG is caused largely by an interaction of a short
negatively charged sequence motif, immediately upstream of the DH-domain and including residues
Asp706, Glu708, Glu710 and Asp712, with a patch on the catalytic surface of the DH-domain
including Arg867 and Arg868. In the absence of both PDZ and RGSL domains, the DH-PH tandem
with additional 21 residues upstream, is 50% autoinhibited. However, within the full-length protein,
the PDZ and/or RGSL domains significantly restore autoinhibition.
Conclusion: Our results suggest a mechanism for autoinhibition of RGSL family of GEFs, in which
the RGSL domain and a unique sequence motif upstream of the DH domain, act cooperatively to
reduce the ability of the DH domain to bind the nucleotide free RhoA. The activation mechanism
is likely to involve two independent steps, i.e. displacement of the RGSL domain and conformational
change involving the autoinhibitory sequence motif containing several negatively charged residues.
Published: 21 May 2009
BMC Structural Biology 2009, 9:36 doi:10.1186/1472-6807-9-36
Received: 13 February 2009
Accepted: 21 May 2009
This article is available from: http://www.biomedcentral.com/1472-6807/9/36
© 2009 Zheng et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Structural Biology 2009, 9:36 http://www.biomedcentral.com/1472-6807/9/36
Page 2 of 14
(page number not for citation purposes)
Background
Rho (Ras-homology) cytosolic GTPases function as
molecular switches that, in the GTP-bound form, interact
with a multitude of effectors that exert control over
cytoskeletal elements, gene transcription, and other bio-
logical phenomena [1-3]. Spatial and temporal control
over these GTPases is exercised by GEFs (guanine nucle-
otide exchange factors), which load up GTP and activate
cognate GTPases, and by GAPs (GTPase activating pro-
teins) which are required by the GTPase for efficient
hydrolysis of GTP to GDP [4,5]. Most of Rho GEFs belong
to the Dbl-homology family of large, multidomain pro-
teins [6]. There are approximately 70 of these proteins in
the human proteome, some highly specific and some acti-
vating indiscriminately two or more different Rho
GTPases [5,7]. The catalytic step is executed by the Dbl-
homology (DH) domain, often assisted by a pleckstrin-
homology (PH) domain, which is invariably located
immediately downstream of the DH domain [6,7]. The
DH domain, either alone or synergistically with the PH-
domain, binds the cognate GTPase in its nucleotide-free
form. Upon release, the GTPase forms a biologically active
complex with the more abundant GTP nucleotide [8]. The
GEFs are thought to be inactive in their nascent form due
to a 'folded', or 'closed' conformation, in which specific
domains or motifs outside the DH-PH tandem bind to
those surfaces on the DH domain which are involved in
the binding of the GTPase [7]. The activation of specific
GEFs requires extra- or intracellular stimuli that directly or
indirectly induce conformational changes in GEFs leading
to release of autoinhibition and expression of full catalytic
potential. While this paradigm may be generally con-
served, details vary depending on the architecture of a par-
ticular GEF.
Recently, structural studies elucidated the mechanism of
autoinhibition in several Dbl-homology GEFs. The proto-
oncogene product Vav, which activates Rac1, is autoinhib-
ited by an N-terminal, helical extension of the DH-
domain which lies in the GTPase interaction site. This
autoinhibition is relieved by Src-mediated phosphoryla-
tion of Tyr174, which is in the center of the autoinhibitory
helix [9]. In Asef, a Rac-specific exchange factor, the activ-
ity of its DH domain is suppressed through an intramo-
lecular interaction with an SH3 domain, found
immediately upstream of the DH module [10,11]. It is
possible that a similar mechanism is also in operation in
other GEFs that show a similar architecture of SH3-DH-
PH modules. In contrast, the Rho-specific p63RhoGEF
contains no identifiable domains other than the DH-PH
tandem, and the autoinhibition is mediated by a con-
served, α-helical C-terminal extension of the PH domain
[12]. Analogous extensions are found in Trio and Kalirin,
and the autoinhibition mode of these GEFs may be very
similar to that of p63RhoGEF [12].
A family of three RhoA-specific GEFs act downstream of
the Gα12/13-coupled receptors (GPCRs). They are:
p115RhoGEF [13], PDZRhoGEF, henceforth referred to as
PRG [14], and LARG [15,16]. This family is distinguished
by the presence of the RGSL (regulator of G-protein sign-
aling-like) domain, upstream of the DH-PH tandem. Fur-
ther, both PRG and LARG contain additional N-terminal
extensions which include a PDZ (PSD-95, Disc-large,
ZO1) domain. Finally, downstream of the DH-PH tan-
dem, all three GEFs contain a ~400 residue long, largely
unstructured region which include a coiled-coil fragment
that mediates homo- and heterodimerization [17].
There is considerable evidence that Gα12/13 activates the
RGSL-family of Dbl-homology GEFs via direct interaction
with the RGSL domain. Crystal structures of these
domains from both p115 and PRG have been determined
[18,19], and additionally the structure of the complex of
the p115 RGSL domain with the Gα12/i3 chimera eluci-
dated the nature of the interaction of both proteins [20].
However, this did not explain how RGSL-domain con-
taining GEFs are activated. Further, it appears that mere
physical interaction does not necessarily result in up-reg-
ulation of GEF activity. For example, the RGSL domain of
p115 has been shown to bind to both Gα12 and Gα13, but
only Gα13, stimulates the GEF activity for p115RhoGEF
and non-phosphorylated LARG [21]. Gα12 will stimulate
LARG when the latter is phosphorylated, although it is not
known why [22]. An excellent review of the interactions of
RGSL-family GEFs with G proteins was published recently
[23].
There is also evidence that the PDZ domain may be
important for the activation of LARG and PRG. Typically,
these relatively small domains are expected to play a role
in targeting proteins to large membrane-associated pro-
tein complexes [24-26]. However, there is evidence that
interactions mediated by the PDZ domains of both LARG
and PRG may also activate their nucleotide exchange
function. For example, plexin-B family of receptors bind
the PDZ domains of both LARG and PRG leading to RhoA
activation [27-29]. It has also been reported that the lyso-
phosphatidic acid receptors, LPA1 and LPA2, bind the
PDZ domain of PRG, and that this interaction leads to
activation of the RhoA pathway in HEK293 cells [30]. The
same PDZ domain was also shown to interact with the
microtubule associated protein 1 (MAP1) light chain and
this interaction modulated the GEF activity [31]. Finally,
the PDZ domain of LARG was shown to bind to CD44
(major hyaluronan receptor), also upregulating RhoA
[32].
Since the mechanism of autoinhibition of the RGSL-family
of GEFs has not been elucidated, it is difficult to speculate
how the interactions mediated by RGSL and PDZ domainsBMC Structural Biology 2009, 9:36 http://www.biomedcentral.com/1472-6807/9/36
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may lead to activation of LARG or PRG, and if they act syn-
ergistically or through alternative and independent mecha-
nisms. In the present study we investigated the question of
the molecular basis of autoinhibition of the RGSL family of
GEFs. We find that the recombinant fragment encompass-
ing residues 37–1081 and including all four key domains
(PDZ, RGSL, DH and PH) of PRG is indeed autoinhibited,
and shows only ~15% of the intrinsic catalytic activity of
the isolated DH-PH tandem. Unexpectedly, the removal of
the PDZ domain, or of a fragment containing both the PDZ
and RGSL domains, has limited effect on the catalytic rates,
which are 18% and 35% of that of the isolated DH-PH tan-
dem, respectively. We identify an autoinhibitory element
within the sequence immediately upstream of the DH-PH
tandem, and we trace the autoinhibition of PRG primarily
to an interaction between a negatively charged sequence
motif, including Asp706, Glu708, Glu710 and Asp712,
and a positive patch on the DH domain that is involved in
the recognition and binding of RhoA. Our results reveal a
complex autoinhibitory mechanism and suggest the possi-
bility that in addition to relief of autoinhibition through
protein-protein interactions, actual up-regulation of the
intrinsic nucleotide exchange activity of GEFs by interacting
partners may constitute a hitherto unrecognized regulatory
mechanism.
Results and discussion
Identification of an autoinhibitory element in the RGSL-
DH linker region
Multidomain fragments of the human PRG were expressed
in E. coli as described in Materials and Methods. We were
not able to express the full-length protein encompassing
residues 1–1522, but we were able to express the core frag-
ment containing the four functional domains, i.e. PDZ,
RGSL, DH and PH, with the connecting linkers, i.e. residues
37–1081. Initial experiments showed that constructs con-
taining a single His6 tag at the N-terminus resulted in
expression of heterogeneous mixtures of products, proba-
bly due to incomplete translation. The problem was effec-
tively solved by replacing the N-terminal His6 tag with a
GST tag and adding a His8 tag at the C-terminus, so that
full-length products could be readily purified using tan-
dem-affinity chromatography. Figure 1 shows a diagram of
the expression plasmid, the constructs which were
expressed and purified in this study and the results of the
nucleotide exchange assay for each, while figure S1 (Addi-
tional File 1) illustrates the purity of the final protein sam-
ples. The shortest fragment comprised only the DH-PH
tandem (PRG712–1081), previously shown by us to have
maximum catalytic efficiency on recombinant RhoA (resi-
dues 1–181) with a nucleotide exchange enhancement of
app. 130-fold compared to spontaneous rates [33].
As judged by the fluorescence assay (see figure 2 for repre-
sentative raw data), all constructs longer than the DH-PH
tandem exchanged GDP for mant-GTP far less efficiently,
consistent with the notion that structural elements
located upstream of the DH-PH tandem inhibit the cata-
lytic function. The construct containing all four domains
(PDZ-RGSL-DH-PH, or PRG37–1081) enhanced the nucle-
otide exchange only 21-fold, and the RGSL-DH-PH con-
struct (PRG277–1081), lacking the PDZ domain, showed
essentially identical activity on RhoA, consistent ~80%
autoinhibition. This baseline activity is comparable to the
levels observed for other GEFs: for example, the C-termi-
nal extension on p63RhoGEF confers 90% inhibition
[12]; for Dbl, the full length protein retains about 10% of
the activity of the isolated DH-PH domain [34]; full
length TIM enhances nucleotide exchange on RhoA 5-
fold, and the removal of the N-terminal 22 residues
increases the effect to 30-fold [35]. A recent study ele-
gantly demonstrated that the baseline activity of Vav1 is
due to an equilibrium between the inhibited, ground
state, and an excited state which is transiently active, high-
lighting the importance of protein dynamics in cell regu-
lation [36].
Unexpectedly, the removal of the RGSL domain (PRG496–
1081) did not relieve autoinhibition, and the resulting pro-
tein showed only 33-fold enhancement in nucleotide
exchange on RhoA, i.e. ~65% autoinhibition. Thus, we
concluded that key elements responsible for autoinhibi-
tion reside within the 200 amino acid linker sequence
between the RGSL and DH domains. Secondary structure
prediction suggests that the linker sequence has propen-
sity to form localized helical structures, although more
than 50% of the sequence is predicted to harbor unstruc-
tured regions (not shown). We were able to express the
linker region (residues 476–711) and a CD (circular
dichroism) spectrum (not shown) was consistent with a
random coil structure. Given that the sequence gave no
clue as to the identity of the functionally important frag-
ment, we expressed additional, progressively shorter con-
structs, i.e. PRG524–1081, PRG630–1081, PRG672–1081  and
PRG691–1081. All retained a significant level of autoinhibi-
tion. We then measured the nucleotide exchange rate on
RhoA in the presence of both the isolated DH-PH tandem
(i.e. PRG712–1081), and the isolated fragment containing
the RGSL domain with the C-terminal linker (i.e. PRG277–
711), or just the recombinant linker (i.e. PRG496–711). Both
experiments gave results identical to those obtained for
the DH-PH tandem alone, indicating that the neither the
RGSL domain, nor the RGSL domain with its C-terminal
extension are capable of interacting with the DH-PH tan-
dem in the absence of a covalent link.
Chemical shift assignment of DH-PH
To probe the molecular mechanism of PRG autoinhibi-
tion we used NMR spectroscopy. The 1H-15N TROSY-
HSQC spectrum of triple-labeled, DH-PH tandemBMC Structural Biology 2009, 9:36 http://www.biomedcentral.com/1472-6807/9/36
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(PRG712–1081) recorded at 800 MHz is shown in figure 3.
Due to the large size of the protein (43 kDa) the spectrum
shows considerable signal overlap. To obtain chemical
shift assignment for the DH-PH resonances, we first
recorded separate spectra for isolated DH and PH
domains. We designed the corresponding constructs
based on the crystal structure of the DH-PH/RhoA com-
plex [37], so that the domains were separated between res-
idues 932 and 933, within the interdomain α-helix. The
two isolated domains, i.e. DH (residues 712–932) and PH
(residues 933–1081), yield spectra of sufficient quality to
allow for backbone assignment using TROSY-based triple
resonance experiments. We achieved nearly complete,
92% assignment of chemical shifts for the isolated DH
domain, and a 70% assignment for the PH domain, which
required 0.6 M NaCl to reduce protein aggregation and
consequent peak broadening.
When we compared the spectra of the DH-PH tandem
with the spectra of the isolated domains, we found that a
vast majority of signals were only slightly shifted, allow-
ing us to use the assignment for the isolated domains to
directly assign the chemical shifts for the tandem. In addi-
tion, we used the sequential connectivities derived from
HNCA and 1H-15N HSQC-NOESY experiments measured
for the tandem. Overall, we assigned 72% of backbone
Multidomain fragments and mutants of PRG generated in this study and their functional characterization; (A) diagrammatic rep- resentation of the expression vector used for all constructs; (B) The constructs used in this study, the kcat values and fold- enhancement of nucleotide exchange compared to uncatalyzed RhoA Figure 1
Multidomain fragments and mutants of PRG generated in this study and their functional characterization; (A) 
diagrammatic representation of the expression vector used for all constructs; (B) The constructs used in this 
study, the kcat values and fold-enhancement of nucleotide exchange compared to uncatalyzed RhoA.BMC Structural Biology 2009, 9:36 http://www.biomedcentral.com/1472-6807/9/36
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amides in the DH-PH tandem: 84% for the DH domain
but only 55% for the PH domain, due to resonance broad-
ening.
Interactions of the autoinhibitory element with the DH 
domain and with RhoA
To assess if the DH-PH tandem is structurally perturbed by
the presence of the N-terminal extensions (i.e. the RGSL-
DH linker fragments), in the autoinhibited constructs
PRG630–1081 and PRG672–1081, we studied both proteins in
solution using heteronuclear NMR. Despite the high
molecular weight of the proteins (>43 kDa), protein deu-
teration allowed us to record high quality 1H-15N TROSY-
HSQC spectra. We compared them to those obtained by
us for the PRG712–1081 fragment (i.e. the isolated DH-PH
tandem). All three spectra are similar, except for addi-
tional peaks due to the unstructured residues from the
linker in the longer constructs (data not shown). The
peaks associated with the DH-PH tandem amides were
superimposable for the two longer constructs, indicating
that the linker does not significantly perturb the structure
of the tandem; this observation is consistent with the
nucleotide exchange assay. However, a detailed analysis of
the 1H-15N TROSY-HSQC spectra measured at 900 MHz
for PRG672–1081 clearly identified a group of amides with
markedly perturbed chemical shifts compared to PRG712–
1081 (Fig. 4A) [38]. We assigned these resonances based on
the assignment obtained for PRG712–1081 and found that
the corresponding residues are within the DH domain
and cluster into three segments: 712–745, 761–779 and
842–878 (see Fig. 4B). The first cluster is located at the
very N-terminus of the DH domain and the changes
observed in this region are likely to be caused simply by
the presence of additional upstream residues. However,
the most interesting changes are observed for the third
cluster of residues, which overlaps with a patch involved
in the interaction with RhoA (Fig. 4C) [37]. This suggests
that the interaction of the linker with the functionally
important surfaces of the DH domain leads to steric inter-
ference and may constitute the basis of the autoinhibitory
mechanism. We did not identify any peaks in 1H-15N
TROSY-HSQC that would indicate the presence of struc-
tured elements within the linker sequence, arising from
the linker sequestered between other structural elements;
however, the crowded spectrum leaves such possibility
open. We conclude that the linker-DH interaction is not
Representative results of the nucleotide exchange assay Figure 2
Representative results of the nucleotide exchange assay. Only half of experimental points are visualized in the graph. 
For other details refer to Materials and Methods.BMC Structural Biology 2009, 9:36 http://www.biomedcentral.com/1472-6807/9/36
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accompanied by the formation of any distinct structural
elements in the linker (e.g. α-helix). However, given the
overall negative charge of the linker and the positive
charges in the proximity of the relevant DH surfaces, the
interaction of the linker with the DH domain is most
likely electrostatic in nature.
In order to determine the position of the linker relative to
the DH domain, we mapped residues with affected chem-
ical shifts onto the crystal structure of the complex. Inter-
estingly, we found that the linker could adopt a
conformation, in which it can interact with RhoA. To test
this we measured spectra of 2H,15N-labeled RhoA in com-
plex with unlabeled DH-PH and PRG712–1081. In both
cases we observed formation of tight complexes, as evi-
denced by slow exchange on NMR timescale. Further, we
also found that the presence of the linker affects chemical
shifts of several amides within RhoA (Fig. 4D). However,
the magnitude of the chemical shift changes is smaller
than that for the DH domain. Therefore, the interaction of
the linker with RhoA is less intimate than that with the
DH domain. Due to the lack of the chemical shift assign-
ments of RhoA in the complex, the detailed analysis of
perturbed residues was not possible.
The nature of the interdomain interactions
The observation that Arg867 and Arg868 in the DH
domain may be affected by interaction with the linker,
prompted us to look at two negatively charged clusters in
the linker: one made up of Glu698, Asp699 and Asp700,
and the second which includes Asp706, Glu708, Glu710
and Asp712. These clusters are reminiscent of the so-
called acidic region of Vav1, harboring the autoinhibitory
helix [39]. A triple mutation E698A, D699A, D700A had
little effect on the catalytic rate, as did truncation resulting
in the PRG701–1081 construct (see above). In contrast, a
charge reversal mutant E698R, D699R, D700R (hereafter
referred to as PRG3R) showed catalytic activity slightly
above that of the isolated DH-PH tandem, suggesting
complete relief of autoinhibition. Further, a charge
reversal quadruple mutant of the second cluster D706R,
E708R, E710R, D712R (denoted PRG4R) showed a signif-
icant increase in catalytic activity, 3.3 fold over the isolated
DH-PH tandem. A possible explanation is that the kinet-
ics of RhoA binding by the DH-PH tandem are altered, i.e.
the off and on rates could be elevated, with no concomi-
tant change in binding affinity for the nucleotide free
RhoA, leading to higher turnover of nucleotide free RhoA
to RhoA￿GTP.
The 800 MHz 1H-15N TROSY-HSQC spectrum of the 0.3 mM DH-PH tandem at 30°C; assignment is shown for two selected  fragments of the spectrum Figure 3
The 800 MHz 1H-15N TROSY-HSQC spectrum of the 0.3 mM DH-PH tandem at 30°C; assignment is shown for 
two selected fragments of the spectrum.BMC Structural Biology 2009, 9:36 http://www.biomedcentral.com/1472-6807/9/36
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The fragment containing residues 672–712, upstream of the DH-PH tandem, interacts with residues within the DH domain and  with RhoA in the binary complex Figure 4
The fragment containing residues 672–712, upstream of the DH-PH tandem, interacts with residues within the 
DH domain and with RhoA in the binary complex. (A) comparison of 900 MHz 1H-15N TROSY-HSQC spectra of DH-
PH (blue) and PRG672–1081 (red) showing chemical shift changes within DH domain induced by the linker; only select fragments 
of the spectrum are shown for clarity (B) a graph showing the magnitude of linker induced chemical shift changes (ΔσHN [Hz]) 
within the DH domain (blue) compared to the surface area of DH residues buried upon formation of the complex with RhoA 
(red); ΔσHN [Hz] were calculated as a differences between chemical shifts for PRG672–1081and DH-PH; the surface buried upon 
complex formation was calculated using the crystal structure of DHPH-RhoA complex and the program MOLMOL [38]; (C) 
crystal structure of the DH-PH/RhoA complex (PDB code 1XCG), showing the residues within the DH domain with the larg-
est amide chemical shift changes induced by the linker (>50 Hz, red; 25 – 50 Hz, orange); the hypothetical position of the 
linker, postulated on the basis of chemical shift perturbations, is shown in yellow; side chains of acidic residues within the linker 
are shown in space filling representation; RhoA is shown as blue ribbon; (D) comparison of 600 MHz 1H-15N TROSY-HSQC 
spectra of RhoA in complex with DH-PH (blue) and PRG672–1081 (red); several RhoA amides with chemical shifts perturbed by 
the presence of the linker are circled.BMC Structural Biology 2009, 9:36 http://www.biomedcentral.com/1472-6807/9/36
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To better understand the role of individual amino acids,
we generated four single-site mutants of the PRG712–1081
construct, i.e. D706R, E708R, E710R and D712R (see
above). The E710R mutant shows significant autoinhibi-
tion (it is actually less active in the in vitro assay than
PRG701–1081), but each of the remaining mutants exhibits
catalytic activity comparable to the isolated DH-PH tan-
dem. It is therefore possible that the observed enhanced
catalytic potential of the PRG4R is due to additive effects of
individual mutations. Interestingly, within the context of
the intact four-domain construct (i.e. PRG37–1081) most of
the autoinhibition is effectively restored, indicating that
both the PDZ and RGSL domains play an important role.
To understand how mutations within the linker modulate
GEF activity, we measured NMR spectra of both the triple
and quadruple charge reversal mutants of PRG672–1081
(henceforth denoted PRG3R and PRG4R) and analyzed the
chemical shifts within the DH domains. We found that
both mutants qualitatively show similar patterns of chemi-
cal shift perturbations as observed for the wild-type
PRG672–1081. However, the magnitude of chemical shift
changes is significantly decreased compared to the wild-
type protein (Figs. 5A &5B). To quantify this effect, we cal-
culated the total chemical shift change, ΔσHN-total, i.e. a sum
of chemical shift changes observed for all amides assigned
to the DH domain, compared to the isolated DH-PH tan-
dem. For PRG672–1081, PRG3R and PRG4R the values of ΔσHN-
total were 875, 480 and 404 Hz, respectively. Therefore, the
mutations within the linker decreased the chemical shift
changes in the DH domain by approximately 50% com-
pared to the wild-type protein. This is consistent with the
observed relief of the inhibitory effect, although it does not
explain the enhanced catalytic activity of PRG4R mutant.
The next step was to evaluate the effect of the mutations in
the linker on the direct interaction of the PRG712–1081 with
RhoA. We measured 1H-15N TROSY-HSQC spectra of 15N-
labeled RhoA in complexes with each of the two mutants,
i.e. PRG3R, and PRG4R. The spectrum of RhoA in the pres-
ence of PRG3R is essentially identical to that of RhoA in the
presence of the wild-type PRG672–1081 indicating no signif-
icant effect of the mutations in the linker on the interac-
tion with RhoA (data not shown). However, noticeable
changes are observed for RhoA in the presence of the
PRG4R with over a dozen resonances shifted by more than
25 Hz (Fig. 5C). As inferred from the NMR analysis, the
linker of the PRG4R mutant appears to interact with nega-
tively charged surfaces of RhoA (Fig. 5D). Reversing the
charge of acidic residues within the linker appears to have
a pronounced effect on the kinetics of DH-PH/RhoA inter-
action and ultimately, the rate of nucleotide exchange.
The role of PDZ-RGSL domains
To evaluate the impact of the mutations in the linker
region on the autoinhibited core fragment of PRG con-
taining all four functional domains, we carried out the
nucleotide exchange assay for PRG37–1081 with the D706R,
E708R, E710R and D712R mutations. The rate of
exchange was increased from ~20, in the wild-type PRG37–
1081, to 43, i.e. only two-fold. Interestingly, this is equiva-
lent to eliminating the PDZ and RGSL domains from
wild-type PRG37–1081. This result shows that autoinhibi-
tion in the wild-type, full-length protein is an additive
effect of a number of different interactions.
Functional assays are consistent with the in vitro model
In order to assess if the in vitro studies are representative of
biological properties of PDZRhoGEF in smooth muscle,
we used a contractility assay of a permeabilized rabbit pul-
monary artery (Fig. 6). In this assay, which measures force
under isometric conditions, we are able to introduce
recombinant protein directly into a smooth muscle strip,
after contractile force is induced at pCa of 6.7. As we
showed elsewhere [37], the addition of the wild-type
recombinant DH-PH domain substantially increases the
contractile force via RhoA activation. When the PRG37–1081
fragment is added instead, the contractile force increases
marginally, consistent with the autoinhibition of that
fragment, while the same fragment with the mutations
D706R, E708R, E710R, D712R, causes a significantly
stronger contraction, albeit well below the DH-PH level,
in full agreement with the in vitro assays.
We then conducted a rhotekin-based assay to measure
RhoA activation in NIH 3T3 cells transfected with full-
length, wild-type human PRG, as well as 3R and 4R
mutants of the full-length protein, and the isolated DH-
PH tandem (Fig. 7). As expected, overexpression of the
isolated DH-PH tandem resulted in significant increase in
RhoA￿GTP over the control. Lower but equal expression
levels of wild-type and the 3R and 4R mutants in unstim-
ulated serum starved cells resulted in greater Rho activa-
tion over control with the 3R and 4R having the greatest
effect. These findings are consistent with significant
autoinhibition of the full length PRG and also show that
the 3R and 4R mutants are biologically active in cells.
The model of autoinhibition
On the basis of the experiments described in this paper we
propose a mechanism for the autoinhibition of PDZRho-
GEF (Fig. 8). Unlike in other GEFs for which similar
mechanisms were rationalized at the structural level,
[11,12,40], the DH domain of PRG is not sterically
obstructed by a single structural element, but instead sev-
eral elements act synergistically within the autoinhibited,
full-length protein. A fragment that spans all functional
domains of PRG, i.e. PRG37–1081, retains only ~15% of the
catalytic activity of the isolated DH-PH tandem, and so we
concluded that intramolecular interactions within this
fragment are primarily responsible for autoinhibition.
This was expected, because RGSL and PDZ domains areBMC Structural Biology 2009, 9:36 http://www.biomedcentral.com/1472-6807/9/36
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The impact of mutations in the linker region on its interaction with the DH domain and with RhoA Figure 5
The impact of mutations in the linker region on its interaction with the DH domain and with RhoA. (A) com-
parison of 600 MHz 1H-15N TROSY-HSQC spectra of PRG672–1081 (black), the two mutants: PRG3R (red) and PRG4R (blue) and 
DH-PH (green); (B) plot of chemical shift differences (ΔσHN) within DH domain induced by the wild-type linker (black), PRG3R 
(red) and PRG4R mutants (blue); (C) comparison of 600 MHz 1H-15N TROSY-HSQC spectra of 2H,15N-RhoA in complex with 
wild-type PRG672–1081 (red) and PRG4R (black); several amides with the largest chemical shift perturbations are circled, peaks 
labeled with asterisks could not be identified in the spectrum of PRG4R; (D) surface charge distribution calculated for the crys-
tal structure of DH-PH/RhoA complex; the putative position of the linker is shown in yellow; side chains of acidic residues 
within the linker are shown in space filling representation; RhoA is delineated by a green boundary for clarity.BMC Structural Biology 2009, 9:36 http://www.biomedcentral.com/1472-6807/9/36
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thought to play a role in the autoinhibition/activation
mechanism. Surprisingly, our in vitro catalytic assay
revealed that removal of both of these domains results in
only 2-fold increase in activity, indicating that other fac-
tors are involved. We traced the primary autoinhibitory
element to a sequence motif upstream of the DH domain,
harboring Asp706, Glu708 and Asp712, and Glu710. The
PRG fragment encompassing residues 691 to 1081, i.e.
with only 21 amino acids upstream of the DH domain,
showed less than 50% of the activity of the DH-PH tan-
dem. Replacing the four negatively charged residues with
arginines not only abolished autoinhibition but gener-
ated a 3.3 fold enhancement of the nucleotide exchange
activity, as compared to the isolated DH-PH tandem.
A model of autoinhibition and activation of PDZRhoGEF Figure 8
A model of autoinhibition and activation of PDZRhoGEF. In the inhibited protein the linker between the RGSL and 
DH domains is sequestered by the two modules, and the DH domain is not accessible to RhoA. Interaction with the Gα subu-
nit, and possibly direct interaction with relevant GPCRs via the PDZ domain, relieve this inhibition by first dislodging the RGSL 
domain and then the inhibitory portion of the linker.
Increase in the endogenous RhoA activation in NIH 3T3 cells  monitored by the Rhotekin assay Figure 7
Increase in the endogenous RhoA activation in NIH 
3T3 cells monitored by the Rhotekin assay. Upper 
panel: Rhotekin pull-down of RhoA￿GTP from cells ectopi-
cally expressing full-length wild type (wt) PRG, the isolated 
DH-PH tandem and the 3R and 4R mutants of the full-length 
form. The cells were under serum free conditions. Bottom 
panel: quantitative assessment of RhoA activation using a set 
of three independent experiments. The isolated DH-PH tan-
dem is not included because the expression level was signifi-
cantly higher than that of the three full-length PRG variants, 
and while the increased endogenous RhoA activity as meas-
ured by the Rhotekin assay (see Methods Section), demon-
strating that these expressed constructs are biologically 
active in cells. Mutant PRG-RhoGEFS were FLAG tagged. 
Western blotting for FLAG indicated that the mutants were 
expressed at an equal level while the DH-PH domain was 
overexpressed (data not shown) accounting for the greater 
level of active RhoA.
Contractility assay Figure 6
Contractility assay. Wild type (wt) and 4R mutant of the 
core fragment of PRG were added to β-escin permeabilized 
pulmonary artery precontracted with pCa 6.7 solution con-
taining 1 μM calmodulin and 2 μM GTP. Concomitant 
increase in force is consistent with activation of the RhoA 
pathway. The 4R mutant, 10–15 μM, induced significantly 
greater Ca2+-sensitized force than the wild type protein (p = 
0.002; n = 11. The magnitudes of the responses are normal-
ized to pCa 6.7-induced force developed before addition of 
the recombinant PRG variants.BMC Structural Biology 2009, 9:36 http://www.biomedcentral.com/1472-6807/9/36
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However, when the mutations were introduced into the
PRG37–1081 core fragment containing all four functional
domains, autoinhibition is largely restored, presumably
by interactions mediated by the RGSL and/or PDZ
domains which may stabilize the autoinhibitory element
in its functional conformation in spite of the mutations.
Based on these results, we suggest that the activation of
PRG, and probably also of the two other remaining mem-
bers of this family of GEFs, i.e. LARG and p115, proceeds
by a multistep mechanism. The primary autoinhibitory
element resides upstream of the DH-PH tandem, but may
not be accessible due to secondary interactions with RGSL
and/or PDZ domains. This is why a conformational
change involving the latter domains is essential, but not
sufficient for full GEF activation. In agreement with this
model, activated, GTP-bound Gα13 can bind directly to a
fragment containing both the linker and DH-PH tandem
of the p115 GEF, but without concomitant activation of
the nucleotide exchange activity [41]. Thus, both the
RGSL domain and the 'activation box' may act synergisti-
cally. Also, activation of GEF activity can be partially
uncoupled from binding of Gα13 to the RGSL domain in
p115 GEF: point mutations in the latter that reduce affin-
ity for Gα13 have no effect on the activation of nucleotide
exchange of p115 GEF [42]. Analogous mutants do not
affect translocation of p115 GEF to particulate fractions in
the presence of Gα13, suggesting that translocation of
p115 GEF is due to complex mechanisms involving ele-
ments other than the RGSL domain [43].
Conclusion
We here propose that in the closed, autoinhibited form, the
RGSL domain interacts with both the RGSL-DH linker and
the DH domain, or perhaps only with the linker, which
serves as the direct inhibitory element (Fig. 7). When the
RGSL domain binds to Gα12/13, the inhibitory element
remains in place, but becomes exposed and accessible to
secondary interactions which in consequence remove the
linker from the functional DH surfaces. The dramatic effect
of the charge reversal mutant also suggests that electrostatic
interactions could play a major role, not only in relieving
the autoinhibition, but also in positive regulation of the
kinetics of RhoA binding and nucleotide exchange. It is typ-
ically assumed that the intrinsic catalytic properties of the
DH domain, or more commonly the DH-PH tandem,
reflect the maximum theoretical nucleotide exchange rate
of the respective GEF. However, this is not always true. The
isolated DH domain of Vav enhances the nucleotide
exchange rate on Rac1 73-fold, but the addition of the PH-
CRD fragment produces a further 13-fold enhancement
[44]. Thus, it is possible that an activating interaction, e.g.
involving Gα subunits, may not only relieve the autoinhi-
bition, but also directly up-regulate the GEF activity. In that
context, we note that the human Gα12 and Gα13 subunits
differ with regard to their pI values, i,e. 9.8 and 8.2, respec-
tively, and the positively charged surfaces could be impor-
tant in the interaction with the DH/RhoA complex.
Finally, we note that the proposed mechanism might be
relevant to all three GEFs of the RGSL-family. The amino
acid sequences of both LARG and p115 show similar neg-
atively charged patches in nearly identical locations:
LARG contains a Glu-Asp-Glu tripeptide, while p115 GEF
has an Asp-Glu-Gly-Glu motif (Additional File 1: Figure
S2). Further work, underway in our laboratories, will
hopefully establish the details of these pathways.
Methods
Protein Expression and Purification
Full-length and truncated versions of human PDZRhoGEF
were PCR-amplified and subcloned into pDEST15 (Invit-
rogene) vector containing a glutathione S-transferase
(GST) tag at the N-terminus, an rTEV protease site
between GST and the insert, and a non-cleavable His8 tag
at the C terminus. All constructs were verified by direct
sequencing prior to protein expression. The proteins were
expressed in the E. coli strain BL21 (DE3) RIPL (Strate-
gene). Cell cultures were grown at 37°C in TB/ampicillin
(100  μg/ml) and chloramphenicol (34 μg/ml), and
induced with 1 mM isopropyl β-D-thiogalactopyranoside
(IPTG) overnight at 18°C. Cell pellets were resuspended
in 50 mM Tris pH 7.8, 300 mM NaCl, 0.5 mM EDTA, 1
mM dithiothreitol (DTT) (Buffer A), lysed using Sonifier
450 (VWR), and clarified by centrifugation at 40,000 × g
for 45 min at 4°C. Supernatant was loaded on a glutath-
ione-Sepharose 4B column (Pharmacia), pre-equilibrated
with Buffer A. Protein was bound to the resin by gently
rocking the column at 4°C for 1 hour and eluted with 20
mM glutathione in 50 mM Tris, pH 8.0, 50 mM NaCl, 0.5
mM EDTA, 1 mM DTT (Buffer B). Fractions containing
pure fusion protein were pooled, digested overnight with
rTEV protease in the same buffer and then dialyzed
against Buffer B to remove glutathione. After rTEV cleav-
age, the protein solution was loaded again on glutath-
ione-Sepharose 4B column and rocked for 1 hour to
remove GST and the uncut fusion protein. Flow-through
was collected and diluted with 50 mM Tris pH 8.0, 150
mM NaCl (Buffer C). The solution was then loaded onto
Ni-NTA column pre-equilibrated with buffer C and eluted
with 200 mM imidazole in Buffer C. Fractions containing
pure protein were pooled and dialyzed against 20 mM Tris
pH 7.5, 150 mM NaCl, 1 mM DTT. Pure protein was con-
centrated and stored at -80°C for the fluorescence assay.
Proteins labeled with stable isotopes (2H, 13C, 15N) were
expressed in minimal media with (15NH4)2SO4 as sole
source of nitrogen and 13C- or 2H,13C-glucose as a source
of carbon. The media were enhanced by the addition of
labeled BioExpress (Cambridge Isotope Labs.). Four types
of labeling scheme were used: 15N, 13C 15N, 2H 15N and 2H
13C 15N.BMC Structural Biology 2009, 9:36 http://www.biomedcentral.com/1472-6807/9/36
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The expression and purification of human RhoAF25N (res-
idues 1–181) was carried out as described previously [45].
Guanine Nucleotide Exchange Assay
Fluorescence spectroscopy analysis of N-methylan-
thraniloyl (mant)-GTP incorporation into RhoA was car-
ried out using a FluoroMax-3 (Jobin Yvon Inc.)
spectrofluorimeter. The exchange reaction was carried out
at 22°C for 5 min in a 1.5 ml Eppendorf tube containing
1 μM GDP-preloaded RhoA and 0.5 μM mant-GTP in 20
mM Tris-HCl, (pH 7.5), 50 mM NaCl, 5 mM MgCl2 and 1
mM DTT. After equilibration, assayed proteins were
added at 0.1 μM concentration and increases in mant-GTP
fluorescence was monitored (λex = 356 nm, λem = 450
nm). The control experiment, in the absence of other pro-
teins, reflects intrinsic exchange activity of RhoA, meas-
ured after equivalent equilibration time. Each exchange
experiment was carried out three times independently.
The initial rates of guanine nucleotide exchange were
determined by regression analysis. The average variation
among measured rate did not exceed 10%. Fold stimula-
tion values were calculated as the ratio of the initial
exchange rate of DH-PH-stimulated reaction to the intrin-
sic rate of exchange for the wild type RhoA.
Optimization of DH-PH samples for NMR experiments
In order to optimize both the stability of protein samples
and the sensitivity of NMR experiments, we screened a large
number of different buffers. We prepared 0.5 mM solution of
DH-PH in several buffers with varied salt concentrations and
kept the samples at 4 – 35°C with periodic monitoring of the
concentration and the level of sample degradation using
SDS-PAGE. We found the best solubility and stability of DH-
PH samples in 50 mM TRIS buffer, pH 7.5 and 150 mM
NaCl. However, such conditions do not provide optimal
sensitivity for cryogenic probes due to high salt concentra-
tion [46]. Therefore, to achieve the highest possible sensitiv-
ity of NMR experiments we tested several salt-free buffers and
found a mixture of 200 mM MOPS/TRIS, pH 7.5, to be opti-
mal. In such conditions DH-PH can remain in solution at a
concentration above 0.3 mM for over a week at 25°C. Higher
temperature, ~30°C, reduces the lifetime of the sample to
approximately 3–4 days.
Because backbone assignment of perdeuterated proteins
depends on efficient back-exchange of amide protons, we
dissolved  15N-labeled DH-PH in D2O based buffer and
monitored H/D exchange using the HSQC spectra. We
observed complete exchange of amide protons over one
week.
Chemical shift assignment
To assign the backbone amide chemical resonances of iso-
lated DH and PH domains, we used standard triple reso-
nance experiments (HNCO, HNCA, HN(CO)CA,
HNCACB, CBCA(CO)NH and 3D 15N-edited NOESY
with 200 ms mixing time). The spectra for 0.3 mM
2H,13C,15N-labeled DH domain in 200 mM MOPS/TRIS
buffer, pH 7.5, and 2 mM DTT were collected using Varian
Inova 600 MHz at 25°C. The spectra for 13C,15N-labelled
PH domain were recorded using Varian Inova 500 MHz
for 0.5 – 0.7 mM protein concentrations in 600 mM NaCl,
50 mM TRIS pH 7.0 and 2 mM DTT buffer at 25°C.
To assign the resonances in the intact DH-PH tandem, we
used 2H,13C,15N labeled protein at 0.3–0.4 mM concen-
tration in 200 mM MOPS/TRIS buffer at pH 7.5 and 2 mM
DTT. The NMR spectra were collected at 30°C using Var-
ian Inova 800 MHz spectrometer equipped with cryogenic
probe. The following TROSY-based experiments were con-
ducted: TROSY-HNCA, TROSY-HNCO, 3D 15N-edited
TROSY-NOESY with 250 ms mixing time.
Chemical shift perturbation experiments
In order to analyze chemical shift perturbations we meas-
ured series of experiments using Varian Inova 900 MHz, Var-
ian Inova 600 MHz and Bruker Avance 600 MHz
spectrometers equipped with cryogenic probes. Samples for
NMR contained 0.2 to 0.3 mM protein concentrations in
200 mM MOPS/TRIS buffer, pH 7.5 with 1 mM DTT. All of
the 1H-15N TROSY-HSQC spectra were collected at 25°C.
Tissue Preparation and Force Measurements
Rabbits were anesthetized and killed with isoflurane.
Small strips (100–150 μm thick, 150–200 μm wide, and
2–3 mm long) of rabbit pulmonary artery were dissected
and freed from connective tissue. Single strips were tied
with monofilament silk to the fine tips of two tungsten
needles, one of which was connected to a force transducer
and mounted in a well on a bubble plate, as described pre-
viously [47]. After measuring contractions induced by
high 154 mM K+, the strips were incubated at room tem-
perature (21–22°C) in Ca2+ free relaxing solution (G1)
containing 4.5 mM MgATP and 1 mM EGTA for several
minutes and permeabilized with 75 uM β-escin for 25
min. This permeabilization protocol permits penetration
of molecules up to 150 kDa [48]. To deplete the sarcoplas-
mic reticulum of calcium [47]. and inhibit NO-synthase
activity, every strip was also treated with 10 μM A23187
(Calbiochem) and 10 μM L-NAME (Sigma) (for addi-
tional 10 min in the G1 solution. Buffer in protein sam-
ples of wild type and 4R mutant PRG core fragment
(PRG37–1081) was exchanged against pCa 6.7, 1 μM cal-
modulin and 2 μM GTP. Samples of ~10–15 μM of recom-
binant protein were used to stimulate the force responses.
The Rhotekin assay
The cDNA of full-length wild-type PDZ-RhoGEF, as well
as 3R and 4R mutants and the isolated DH-PH tandem
were PCR amplified with flanking restriction sites and
introduced into p3XFLAG-myc-CMV-24 mammalian
expression vector (Sigma-Aldrich, St. Louis MO). NIH 3T3BMC Structural Biology 2009, 9:36 http://www.biomedcentral.com/1472-6807/9/36
Page 13 of 14
(page number not for citation purposes)
cells were cultured on a 10 cm culture plate in Dulbecco's
Modified Eagle Medium (DMEM; Invitrogen-Gibco) sup-
plemented with 10% fetal bovine serum (FBS; Invitrogen-
Gibco) at 37°C in 5% CO2. The plasmids for the ectopic
expression with N-terminal 3XFLAG and C-terminal myc-
tag, and coding sequences for the full-length wild-type, 3R
or 4R mutant PDZ-RhoGEF or the DH-PD tandem were
transfected into cells using Lipofectamine 2000 (Invitro-
gen) following manufacture's standard protocol. The cells
were treated for transfection, cultured overnight, treated
for transfection for the second time and cultured in
DMEM without FBS, changed 8 hours after the second
transfection, overnight. RhoA activation was determined
by precipitation of active GTP-bound RhoA (RhoA￿GTP)
with a glutathione S-transferase (GST)-fusion protein of
the Rho-binding domain (RBD) of the Rho effector
rhotekin as previously described [49]. Briefly, the cells on
a 10 cm plate were lysed in 500 μl of ice cold lysis buffer
(25 mM HEPES, pH 7.5; 150 mM NaCl; 1% NP-40; 10
mM MgCl2; 1 mM EDTA; 6% Glycerol; 1% Protease
inhibitor cocktail (Sigma-Aldrich, St. Louis MO)), and
cleared by centrifugation at 14,000 g for 10 minutes at
4°C. Ectopic expression of full-length wild-type, 3R and
4R mutant PDZ-RhoGEF at an equal level and the DH-PD
tandem over-expression were confirmed by subjecting the
supernatant to Western blotting for FLAG epitope tag
(data not shown). The supernatant was added to GST-
RBD agarose beads (Millipore, Billerica MA) and affinity
precipitated active RhoA￿GTP was detected by Western
blotting for RhoA using a mouse monoclonal antibody
(Santa Cruz Biotechnology Inc., Santa Cruz CA). Detec-
tion and quantification of the signal was performed using
the Odyssey system software (Li-Cor, Lincoln NE).
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